The precision Treg-engineered donor product Orca-T exhibited preventive potential for graft-versus-host disease (GVHD) in patients with high-risk hematologic malignancies who underwent hematopietic stem cell transplantation (HSCT), with less immunosuppression compared with the standard of care (SOC) in a multicenter experience, according to the early findings presented during the 2020 ASH Annual Meeting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,